Actinium Pharmaceuticals (ATNM) CEO On New Radiotherapy Candidate For Cancer Patients

<p>Actinium Pharmaceuticals (ATNM) is a clinical-stage biopharmaceutical company. CEO Sandesh Seth discusses ATNM which is developing a new radiotherapy candidate for cancer patients. The company released promising results from trials of its radiotherapy candidate IOMAB-B which could help patients with relapsed or refractory acute myeloid leukemia receive bone marrow transplants. He then goes over the outlook for the company. Tune in to find out more about the stock market today.</p>